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Recent studies (1-3) have indicated that glucose can react nonenzymatically
with amino groups of a wide range of proteins throughout the body, including
intracellular proteins such as hemoglobin and lens crystallins, extracellular pro-
teins such as collagen, and cell membrane proteins on red cells(1) andendothelial
cells (2, 3). Initially a reversible adduct, the Amadori product is formed from
the nonenzymatic reaction of glucose with proteins (4, 5). However, these
Amadori products can slowly undergo a series offurther reactionsand rearrange-
ments that give rise to complex irreversible protein adducts, advanced glycosyl-
ation endproducts (AGE).' These AGE continue to accumulate in extracellular
and membrane proteins as a function of time and glucose concentration (2, 6).
Recently, a newmembrane-associatedmacrophagereceptorhas been identified
that recognizes proteins modified by this process of long-term nonenzymatic
AGEformation (7, 8). This receptorhas been shown not torecognize low-density
lipoprotein (LDL), acetyl-LDL, mannose/fucose, and formaldehyde-treated pro-
teins (9). Because formation of AGE increases with protein age (9-11) and AGE
receptor-mediated uptake and degradation of these proteins increases with
amountofAGEformation (7), it hasbeen postulated (7, 8) that the AGE receptor
preferentially mediates the removal of senescent macromolecules. In disorders
such as diabetes mellitus, in which accelerated AGE formation occurs (2), the
efficiency of such a removal mechanism may influence the rate at which diabetic
tissue damage develops.
Reasoning that certain cells have a long enough lifespan to allow AGE forma-
tion on their surface proteins, we hypothesized that the AGE receptor might
also mediate the removal of aging cells by selectively recognizing a cell-surface
alteration that accumulates over time. This mechanism would also account for
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the increased removal rate of red cells observed in diabetes, where prolonged
hyperglycemia is associated with accelerated AGE formation and shortened red
cell survival (11). In this report, we describe a series of experiments in which
intact cell recognition and binding by the AGE receptor was evaluated, using the
red blood cell as a model.
Materials and Methods
RBC Preparation.
￿
Human blood (2.0 ml) from normal, healthy adult volunteers was
collected in heparinized tubes. After removal of plasma and huffy coat, the RBCs were
washed four times with 10 vol of Ca"- and Mg"-free PBS, pH 7.4, and were resuspended
in DMEM.
BALB/cJ mice (The Jackson Laboratory, Bar Harbor, ME) were rendered diabetic by
intraperitoneal injection of freshly prepared alloxan monohydrate (40 mg/kg) dissolved
in 0 .1 M sodium phosphate buffer (pH 3.0). The presence of diabetes was assessed by
measuring serum glucose concentrations with a glucose analyzer (Bio-Dynamics, Indian-
apolis, IN) 48 h after injection and at weekly intervals thereafter. All diabetic animals had
plasma glucose concentrations >300 mg/dl. 3 mo after alloxan administration, mouse
erythrocytes were collected in heparinized tubes and prepared as described above for
human RBC.
Opsonized RBC Preparation.
￿
0.1 ml of a 15% RBC suspension from a D* donor was
added to 0.5 ml of a high-titer anti-D serum . After incubation at 37'C for 30 min, the
cells were washed three times with PBS and resuspended in 3 ml of DMEM.
AGE-RBC Preparation. The specific AGE [2-furoyl-4-(5)-(2-furanyl)-1H-imidazole]-
hexanoic acid] (FFI-HA) was synthesized as described previously (12). In brief, furylglyoxal
hydrate (10 mmol) in 3 :1 dioxane/water was treated with 6-amino hexanoic acid (15
mmol) and triethylamine (15 mmol) and stirred at 25°C for 1 h. After the addition of
concentrated aqueous ammonia, the mixture was diluted with 5% NaH2PO4 and extracted
with CH2CI2, washed with brine and filtered through active carbon and MgS04. The
crude product was purified by medium pressure chromatography on silica gel yielding
FFI-HA as straw-colored flakes (melting point 105-106°C).
Freshly washed normal RBCs were resuspended in PBS, with and without 10 mM of
the water-soluble carbodiimide, 1-cyclohexyl-3-[2-(4-morpholinyl)-ethyl]-carbodiimide
(CMC) (12), to which FFI-HA was added at different concentrations (10-100 UM). The
mixtures were incubated with continuous mixing for 1 h at room temperature. Parallel
mixtures containing RBCs alone in PBS or RBCs and carbodiimide (10 mM) were treated
identically as controls. After three washes, the cells were resuspended in 1 mM glycine in
PBS and left to incubate for 30 min. After three washings with PBS, the cells were
suspended in RPMI 1640 before phagocytosis assay.
Glycosylated RBC Preparation.
￿
To produce nonenzymatically glycosylated erythrocytes,
glucose, glucose-6-phosphate (G-6-P), xylose, arabinose, fructose, and galactose were
added to freshly isolated normal human red cells suspended in DMEM at a concentration
of 100 mM and incubated for 48 h at room temperature. RBC suspensions without added
sugars were used as control cells. Afterincubation, the cellswere washed three times with
PBS and were suspended in RPMI 1640.
AGE-BSA was prepared by incubating BSA in 50 mM glucose at 37°C for 6 wk, in the
presence of protease inhibitors (PMSF, 1 .5 mM; EDTA, 0.5 mM) and antibiotics (penicil-
lin, 100 U/ml; gentamicin, 40 mg/ml) as described previously (7, 8).
To determine the amount of FFI bound to red cell membrane protein and membrane-
bound FFI, erythrocyte ghosts from FFI-coupled RBCs, as well as from the various control
and sugar-incubated RBCs were prepared according to the method of Dodge et al. (14)
and were stored at 4°C in 5 mM sodium phosphate buffer, pH 8.0. Protein determinations
were performed according to the method of Bradford et al. (15) after solubilizing aliquots
of ghost RBCs in 1 N NaOH. Membrane-bound FFI was determined by radioimmunoas-
say, as described previously (16). FFI-RBC contained 371 pmol/mg membrane protein ;
opsonized RBC, 7.1 pmol/mg; and PBS-RBC, 8.9 pmol/mg of membrane protein.VLASSARA ET AL.
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Glucose-RBC contained 168 pmol/mg; G-6-P-RBC, 209 pmol/mg; xylose-RBC, 240
pmol/mg; and arabinose-RBC, 280 pmol/mg of membrane protein.
Human Monocyte Preparation.
￿
The buffy coat from 100 ml fresh human blood was
diluted twofold with saline containing 1 mM EDTA, pH 7.4, and mononuclear cells were
separated from other elements of the blood by centrifugation on Ficoll-Paque gradients
as described before (17). The mononuclear cells were washed three times in cold RPMI
1640 (Gibco, Grand Island, NY) to remove platelets, and the cells were suspended in
RPMI 1640 made 10% in normal human serum. The monocytes were further purified
by the Percoll method (18, 19). Percoll was brought to isotonicity by the addition of 0.1
vol of IOX PBS. 1 ml of normal human serum, 14.7 ml PBS, and 22 ml isotonic Percoll
was mixed in sterile 50-ml centrifuge tubes and centrifuged for 25 min at 8,000g at 5°C
in a Sorvall SS-34 rotor. 5 ml ofthe mononuclear suspension were layered on the resulting
gradients, and the tubes were centrifuged at 1,500 g for 25 min at 5'C in a swinging-
bucket rotor. The resulting bands were detected by light scattering, and band I, corre-
sponding to monocytes, was transferred and cultured in screw-cap Teflon jars (Savillex,
Minnetoka, MN), at 106 cells/ml in RPMI 1640 with 12.5% human serum at 37° C in 5%
C02 for 5-7 d. Cell viability was assessed by trypan blue exclusion . Plating efficiency of
phagocytes on a tissue-culture plastic surface was measured before and after attachment.
>99% of the adhering cells were monocytes, as assessed by their ability to spread on
surfaces (19) and ingest IgG-coated erythrocytes (20). When ready for use, aliquots of 106
monocytes were plated in sterile petri dishes containing precleaned round coverslips, and
incubated for 2 h at 37°C in 5% C02. After the appropriate washes, ^" 7 .0 X 105 cells
adhered routinely.
Phagocytosis Assay.
￿
Before the addition of RBCs, the monocyte cultures were washed
twice with RPMI 1640. The various red cell suspensions were added to each well to give
a 100-fold excess of red cells to monocytes, and the cells were then incubated at 37 °C for
up to 2 h. At the indicated times the coverslips were removed from the wells, washed
three times with RPMI to remove nonadherent material, placed into clean wells, and
fixed with 1 .25% glutaraldehyde in PBS for 30 min. Duplicate coverslips were counted
using 40 X phase microscopy. At least 300 monocytes from three or more randomly
selected fields were counted per well, and duplicate wells were evaluated for each data
point. The data were expressed as the number of positive monocytes (monocytes with
erythrocytes ingested) per 100 monocytes (21, 22). Ingestion index, the number of
ingested red cells per positive monocyte, was also determined (23).
Mouse Peritoneal Macrophage Preparation. Resident mouse peritoneal macrophages
were isolated from BALB/cJ female mice as described previously (21, 23), and plated in
wells containingglass coverslips as described above for human monocytes. The phagocy-
tosisofmouse red cellsfrom normal and diabetic BALB/cJ mice by syngeneic macrophages
was performed identically with that described above for human RBC. Inhibition experi-
ments were carried out in the absence and presence of saturating concentrations of AGE-
BSA (0.1-1.0 mg/ml of medium) (7-9). Opsonized human RBC prepared as described
above were used as controls. In these experiments the data are expressed as percentage
of macrophages having five or more ingested RBC per macrophage.
FFI-RBCHalf-life Assay.
￿
BALB/c inbred mice were bled by cardiac puncture, yielding
^-2.0 ml of blood. The red cells were washed with 10 vol Ca"- and Mgt'-free PBS and
coupled with FFI in the presence of 10 mM CMC as described above. RBCs incubated in
PBS with and without CMC were used as controls. Subsequently all cell suspensions were
labeled with "Cr by adding 0.2 mCi Nat["Cr]0, (New England Nuclear, Boston, MA) to
2 ml of 50% packed RBC in RPMI-1640 medium for 1 h at 37°C. The labeled cells were
washed with PBS at least four times to remove unbound isotope. Three BALB/c mice
were then injected intravenously with 200,ul ofeach of the four types of RBC suspension,
containing 7.5 X 105 cpm. At the indicated times, mice were bled (0.05 ml) and level of
radioactivity was determined.
Statistics.
￿
All data are expressed as mean ± SEM of six experiments. p values were
obtained using Student's unpaired t test.542
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FIGURE 1 .
￿
Humanmonocyte phagocytosis ofhu-
man erythrocytes chemically coupled to the spe-
cific AGE, FFI (dark bar), after 7 d of culture.
IgG-opsonized red cells (IgG-RBC), phosphate-
buffered saline-treated cells (PBS-RBC) and cells
treated with water soluble carbodiimide (see Ma-
terials and Methods) (CMC-RBC) were used as
controls (open bars). Data representing the mean
t SEM of six different experiments, each per-
formed in duplicate, are expressed as percent of
monocytes with ingested erythrocytes.
When 7-d-oldcultured human monocytes were exposed for 2 h to FFI-coupled
RBCs, a large number of monocytes (55 ± 6%) bound the modified red cells
(Fig. 1). This number was significantly higher than the binding of control PBS-
treated cells (4 ± 2%) (p < 0.0025) or cells that were incubated in carbodiimide
alone (6 ± 0.9%) (p < 0.0025) and almost as high as that observed with IgG-
coated red cells (70 ± 9%). Similarly, the phagocytic index of FFI-treated RBCs
was significantly greater (3.4 ± 0.8) than both normal control (1.2 ± 0.2) (p <
0.0025) and carbodiimide-treated cells (1.5 ± 0.2) (p < 0.0025), but less than
that of IgG-coated RBCs (4.9 ± 1.6).
To differentiate surface-attached from ingested erythrocytes, a hypotonic
solution (PBS diluted 1:4 in water) was added to selected wells for 10 s, followed
by the addition of fixative. Maximal monocyte endocytosis of FFI-RBC was
complete within 60 min, in contrast to opsonized cells, which were maximally
ingested within 30 min.
Exposure of FFI-coupled RBCs to monocytes cultured for 1-9 d revealed that
maximal uptake of FFI-coupled red cells occured on day 7 (Fig. 2). Significant
uptake was noted on day 1, followed by a rapid decline over the next 48-96 h
and a subsequent increase of uptake from days 3 to 7. The uptake of opsonized
cells was uniform throughout the entire incubation period.
To establish the specificity of the interaction of FFI-RBCs with human mono-
cytes, competition experiments were carried out in which binding and ingestion
of red cells were observed in the presence and absence of nonenzymatically
glycosylated BSA (AGE-BSA), prepared as described in Materials and Methods
(12). As shown in Fig. 3, the addition of AGE-BSA at a concentration of 500
jug/ml inhibited monocyte binding ofFFI-RBCs by >70% and binding ofnormal
PBS-treated RBCs by 10-20%. In contrast, AGE-BSA did not inhibit IgG-RBC.
Similar results were observed with 1 .0 mg/ml of inhibitor (data not shown).v m
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FIGURE 2.
￿
Effect of in vitro culture of normal human
monocytes on binding of FFI-RBC (dark circles), pre-
pared as described in Materials and Methods. IgG-RBC
(opencircles) and PBS-RBC (open triangles) were used as
controls. Data, representing the mean ± SEM of three
different experiments, each performed in duplicate, are
expressed as percent of monocytes with ingested eryth-
rocytes.
FIGURE 3.
￿
Competitive inhibition of FFI-RBC binding by
normal 7-d-old human monocytesby excess AGE-BSA (dark
bars). IgG-RBC and PBS-RBC were used as controls. Data,
representing the mean t SEM of six differentexperiments,
each performed in duplicate, are expressed as percent of
monocytes with ingested erythrocytes. 100% values were
FFI-RBC 55 ± 6, IgG-RBC 70 ± 9, and PBS-RBC4 ± 2.
These data suggested that FFI-modified red cells are recognized and bound
specifically by the monocyte AGE-binding site.
We subsequently induced accelerated AGE formation on red cell surface
proteins by a 48-h, 25°C incubation of human RBC with different sugars,
(glucose, G-6-P, xylose, arabinose, galactose, and fructose) at 100 mM concen-
trations. At the end of this period, the media demonstrated no evidence of cell
lysis, and red cells appeared microscopically indistinguishable from the controls.
As demonstrated by RIA (Materials and Methods section), red blood cells
incubated in the presence ofhigh glucose and G-6-P concentrations underwent
formation of a significant amount of AGE on their cell membrane proteins.
Uptake of RBCs from each group was determined by the human monocyte
phagocytosis assay. As indicated in Fig. 4, 15% ofthe monocytes bound glucose-
incubated RBCs and 26% bound G6P-treated RBCs, as compared to 6% of
monocytes binding control PBS-RBCs. Similarly, fructose- and galactose-incu-
bated RBCs bound to 12.5 and 16.5% of the monocytes, respectively. A much
lower number of monocytes bound red cells that had been preincubated with
either xylose or arabinose (7.5% for each).
When in vivo glucose-modified diabetic mouse RBCs were added to normal
mouse macrophages, a significant increase in phagocytosis was observed in
comparison to that of normal red cells (21.5 vs. 8.2%, p < 0.005) (Fig. 5A).
Competition with excess AGE-BSA revealed inhibition ofdiabetic red cell inges-
tion by 70%, and inhibition of normal red cell ingestion by 25%. In contrast, in544
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FIGURE 4.
￿
Normal 7-d-old human monocyte binding of
erythrocytes previously incubated in 100 mM concentra-
tions of either glucose, glucose-6 phosphate, xylose, ara-
binose, fructose or galactose for 48 h at 25°C. IgG-RBC
and PBS-RBC were used as controls. Data, representing
the mean ± SEM of six different experiments, each
performed in duplicate, are expressed as percent of mon-
ocytes with ingested erythrocytes.
FIGURE 5.
￿
(A) Normal mouse peritoneal macrophage bind-
ing of diabetic syngeneic erythrocytes. Data are expressed as
the mean ± SEM percentage of monocytes with bound
erythrocytes. (B) Inhibition of binding of diabetic red cells
by excess AGE-BSA (500 Wg), shown as percent of(A) values.
Normal PBS-treated mouse red cells (NC-RBC) and IgG-
coated human red cells (IgG-RBC) were used as controls.
Values represent three different experiments, each per-
formed in duplicate.
similar experiments with opsonized erythrocytes, AGE-BSA failed to compete
even at maximal AGE-BSA concentrations (1 mg/ml) (Fig. 5B). To determine
whether autologous red blood cells modified by an AGE such as FFI-HA are
recognized by macrophages in vivo and removed from the circulation faster than
nonmodified cells, BALB/c inbred mouse red cells were incubated either with
FFI-HA (as described in Materials and Methods), or with PBS alone for 1 h at
room temperature. As an additional control, mouse cells were treated with
carbodiimide alone (10 mM). After "Cr-labeling, all three groups of cells were
reinjected intravenously into syngeneic mice and erythrocyte radioactivity was
monitored for 20 d. Within the first h after injection, ^-9% of the initial
radioactivity was found in the serum fraction of all three groups. This was100
E
a
80
0
° u 60
0
0 -- 40
V
m
o:
20
U
VLASSARA ET AL.
￿
545
FIGURE 6.
￿
Half-life of BALB/c inbred mouse
"Cr-labeled FFI-RBCs after intravenous injec-
tion into syngeneic mice (75 x 10s cpm/200
"
￿
A1/mouse), as function of time (d). "Cr-labeled
°
￿
PBS-treated RBC (dark circles) and carbodi-
imide-treated RBCs (open rectangles) were used
as controls. Values representtheaveragepercent
of cpm, 24 h after injection, from two different
experiments, each performed in groups of three
BALB/c mice.
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presumably due to traumatic hemolysis caused by ex vivo handling, since it was
reduced to 0.4% in all three groups within the first 24 h. As shown in Fig. 6, the
half-life ofFFI-treated red cells was observed to be 7 d, compared to the control
cell half-life of20 d. This value for the control cells is in agreement with previous
studies in mice using the same method (24). Cells treated with carbodiimide
alone had a nearly normal in vivo half-life.
Discussion
In this report we have extended our previous observations on the recognition
of AGE on proteins by a specific monocyte/macrophage receptor. We now
present evidence that both synthetic and naturally formed AGE adductsattached
to the surface of intact human cells induce binding and ingestion of these cells
by normal human monocytes. The recognition and removal of these modified
cells appears to be mediated by the specific macrophage AGE receptor, since
AGE-modified red cell binding is specifically inhibited by competitive binding of
AGE-BSA (7-9). We further demonstrate that the presence of AGE on the red
cell surface in amounts significantly greater than found on unmodified cells leads
to a shortened erythrocyte survival in vivo, presumably due to the more rapid
removal of these AGE-cells by splenic and hepatic phagocytic cells.
Red cells were selected as an appropriate model for two reasons. First,
erythrocytemembrane proteins are synthesizedduring erythropoiesis andremain
intact, with negligible turnover, throughout the cell's 3-4 mo lifespan (1, 25).
These proteins thus survive long enough for AGE formation to occur. Second,
enhanced Amadori product formation has been demonstrated previously on
diabetic red cell membrane proteins (1) in association with shortened red cell
survival in vivo (26).
Nonenzymatically glycosylated proteins normally undergo a slow series of
further reactions and rearrangements leading to the formation of irreversible
AGEs that accumulate with protein age (4). These accumulating AGES are
specifically recognized by the macrophage AGE receptor (7), and thus appear to
function as a time-dependent signal forthe removalofsenescent macromolecules.
Because human red blood cells survive for a prolonged period of time, it was
hypothesized that the increasing amounts of AGE, which would form progres-
sively on their surface, would trigger removal from the circulation via the specific546
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AGE receptor system. The results of the above studies are consistent with this
hypothesis.
Nonenzymatic glycosylation oferythrocyte membrane proteins hasbeen shown
previously (1) to be extensive and relatively nonspecific, occuring primarily at
the lysine residues of most major protein bands. In this report, we demonstrate
that AGE are also present on normal intact red blood cells, and that AGE
accumulation can be accelerated by exposure to high glucose levels, which in
turn leads to increased monocyte AGE receptor bindingand ingestion ofglucose-
modified red cells. Values obtained for red cell membrane AGE content may be
higher than amounts available to interact with the macrophage AGE receptor in
vivo, since the RIA method used in these studies for the measurement of AGE
involves enzymatic hydrolysis of AGE-proteins (16). This may expose AGE
adducts that are normally hidden.
Although the in vitro glucose concentration used in these experiments (100
mM sugar) was nonphysiologic, it was chosen to accelerate the formation of
reactive AGE over the short, experimentally practical incubation period used,
since 2-3 d ofalbumin incubation with the same glucose concentration in vitro
has been shown previously (27) to result in detectable AGE formation. Because
it is the integral of glucose concentration over time that determines the extent
of AGE accumulation (2), this process occurs over a much longer period in vivo
(10, 27-29), where concentrations of glucose found even in diabetic plasma
rarely exceed 20 mM. After 3 mo ofexposure to hyperglycemia, however, RBCs
fromdiabetic mice showedatwofold increase in ingestion by mouse macrophages
through the AGE receptor.
The increased AGE formation and binding oferythrocytes to monocytes after
incubation with G-6-P compared to glucose, fructose, and galactose, reflects the
ability ofG-6-P to more readily form AGE, due to a higher percentage ofreactive
open-ring G-6-P molecules at equilibrium (24). The pentoses, xylose, and arabi-
nose also react with protein amino groups faster than glucose to form a series of
pigmented glycosylation products of undetermined structure (30). Surprisingly,
however, these products did not induce binding and uptake by macrophages
above that of normal control cells, despite an increased amount of FFI-like
material, as measured by RIA. Evidently, the anti-FFI polyclonal antibody used
in our assay recognizes and crossreacts with FFI-like products in these arabinose
and xylose reactions. The AGE-receptor, on the other hand, appears to be more
restrictive in its structural requirements. This phenomenon warrants further
investigation, since the formation ofdifferent AGE with structures not recogniz-
able by the AGE receptor or other scavenger monocyte receptors may result in
accumulation of unremoved proteins in vivo.
In addition to increasing red cell uptake through interaction with the AGE
receptor, accumulation of AGE on proteins of aging normal and diabetic red
blood cells may also contribute to the removal ofsenescent erythrocytes by other
receptor-mediated mechanisms as well. Nonenzymatic glycosylation results in
increased crosslinking of proteins by facilitating formation of both disulfide
bonds and glucose-derived, FFI-like crosslinks (4, 27, 31). In red cells, such age-
related, glycosylation-dependent crosslinking (6, 31) may be responsible for the
clustering of membrane proteins that is thought to be necessary for the appear-VLASSARA ET AL.
￿
547
ance of a unique senescent cell antigen with age (32-35). This antigen, which
may be exposed by the process of clustering or which may arise de novo as a
consequence of clustering, is then recognized by an IgG autoantibody that
mediates subsequent recognition and uptake by macrophages (32). Similarly, the
appearance of membrane glycoproteins recognizable by the N-acetyl-D-galactos-
amine receptor of hepatic Kupffer cells (36) could also arise by this mechanism.
Whether the senescent or glucose-modified cells of other tissues are eliminated
via this mechanism is an important question that warrants further investigation,
since removal-associated cellular damage could play a critical role in the devel-
opment of tissue pathology in both aging and diabetes.
Summary
Glucose can react nonenzymatically with amino groups of proteins to form
covalent Amadori products. With time theseadductsundergo further rearrange-
ments to form irreversible advanced glycosylation endproducts (AGE), which
accumulate with protein age. A specific AGE, 2-(2-furoyl)-4(5)-(2-furanyl)-1H-
imidazole (FFI), has been identified on proteins in vivo. We have recently shown
that a macrophage receptor specifically recognizes and internalizes proteins
modified by AGE such as FFI, thus preferentially degrading senescent macro-
molecules.
Reasoning that cellular turnover may be mediated by macrophage recognition
of AGE-membrane proteins, we prepared human RBCs with FFI attached
chemically. Human monocytes were incubated with either FFI-RBCs, IgG-
opsonized RBCs, or PBS-treated RBCs. Erythrophagocytosis of FFI-RBCs was
significantly higher than that of PBS-RBCs (55 vs. 4% ; p < 0.0025) and almost
as high as that of IgG-RBCs (70%), and was competitively inhibited by AGE-
BSA. AGE-RBCs were also prepared by incubating RBCs with various sugars.
Human monocytes showed a 15% ingestionofglucose-RBCs, anda 26% ingestion
of glucose-6-phosphate-RBCs, compared to 6% for PBS-RBCs. Similarly, dia-
betic mouse RBCs were phagocytosed by nearly three times more cells (21%)
than normal mouse RBCs when exposed to syngeneic mouse macrophages. This
phagocytosis was competitively inhibited (70%) by addition of excess AGE-BSA.
The in vivo half-life of "Cr-labeled mouse FFI-RBCs injected into syngeneic
mice was reduced to 7 d, as compared to a half-life of 20 d for the controls.
These data suggest that the macrophage receptor for the removal of glucose-
modified proteins may also mediate the endocytosis of RBCs with AGE formed
on their surface, and thus be responsible in part for the removal of some
populations of aging cells.
Receivedfor publication 6 April 1987.
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